2018-11-15T13:44:31-06:00 2017-12-31 KPMG LLP 345 Park Ave New York NY 101540102 990 2017-01-01 820656623 The Silverstein Foundation for Parkinson's with GBA % JONATHAN T SILVERSTEIN SILV 9175198108 PO BOX 237137 NEW YORK NY 10023 JONATHAN T SILVERSTEIN PRESIDENT 9175198108 2018-11-15 true MICHAEL G MCGEE P00542288 2127589700 2018-11-15 167.68.102.5 13407320183195000066 2018-11-15 P 90E542974120B81153546E5C9C70F775FE1D9C3E D910802595CA98950818687B702B3FAC40284F54 2017 2019-02-21 02:37:17Z X JONATHAN SILVERSTEIN PO BOX 237137 NEW YORK NY 10023 6231700 false X WWW.silversteinfoundation.org X 2017 NY TO RAISE AWARENESS AROUND PARKINSON'S DISEASE ASSOCIATED WITH GBA MUTATIONS AND RELEVANT CLINICAL TRIALS FOR MUTATION CARRIERS. 2 2 0 0 0 0 0 6217058 0 0 0 14642 0 0 0 6231700 0 940249 0 0 0 0 0 0 0 0 133176 0 1073425 0 5158275 0 5199155 0 40880 0 5158275 THE SILVERSTEIN FOUNDATION FOR PARKINSON'S WITH GBA RESEARCH RAISES AWARENESS AROUND PARKINSON'S DISEASE ASSOCIATED WITH GBA MUTATIONS. WE AGGRESSIVELY SEEK OUT NEW CUTTING EDGE THERAPEUTIC APPROACHES TO TREATING AND PREVENTING PARKINSON'S IN GBA MUTATION CARRIERS. THROUGH CLINICIANS, SCIENTISTS AND BIOTECH COMPANIES, WE SEEK TO ACCELERATE RESEARCH AND CLINICAL TRIALS IN AN EFFORT TO RAPIDLY BRING NEW THERAPEUTIC OPTIONS TO PATIENTS. false false 940249 940249 DONATIONS TO VARIOUS CLINICIANS, SCIENTISTS AND BIOTECHNOLOGY COMPANIES TO ACCELERATE RESEARCH AND CLINICAL TRIALS IN AN EFFORT TO BRING NEW THERAPEUTIC OPTIONS TO PATIENTS. 940249 true true false false false false false false false false false false false false true false false false false false false false false false false false false true false false false false false false false false false false true false false false false false false false false false 3 0 0 false false false false false false false false false X 2 2 true false false false false false false true true false false true false false false false false true false NY X JONATHAN T SILVERSTEIN 9175198108 11 RIVERSIDE DRIVE APT PH-W2 NEW YORK NY 10023 X JONATHAN SILVERSTEIN PRESIDENT / SECRETARY 2.0 0.0 X X 0 0 0 NATALIE SILVERSTEIN VICE PRESIDENT / TREASURER 1.0 0.0 X X 0 0 0 0 0 0 0 false false false 0 X 6217058 50178 6217058 0 14642 14642 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6231700 14642 940249 940249 0 0 0 0 0 0 0 0 0 0 57273 57273 0 0 0 0 44003 44003 30043 30043 0 0 0 0 0 0 0 0 0 0 0 CORPORATION FILING FEES 203 203 TECHNOLOGY EXPENSE 1548 1548 MISCELLANEOUS 36 36 OTHER TAXES 70 70 1073425 940249 133176 0 X 0 5098977 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 50178 0 50000 0 0 0 0 0 0 0 5199155 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 40880 0 40880 X 0 0 0 0 0 5158275 0 5158275 0 5199155 5158275 X false false false X 0 0 0 0 6217058 6217058 0 0 0 0 0 0 6217058 6217058 5006098 1210960 14642 14642 0 0 6231700 X 0 DUE TO BROKER 40880 40880 false PARKINSON'S INSTITUTE AND CLINICAL CENTER 675 ALMANOR AVENUE SUNNYVALE CA 94085 943061594 501(c)(3) 125000 N/A funding to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients. THE MICHAEL J FOX FOUNDATION 469 7TH AVENUE 498 NEW YORK NY 10018 134141945 501(c)(3) 25000 N/A funding to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients. COLUMBIA UNIVERSITY SCHOOL OF MEDICINE 630 W 168TH ST NEW YORK NY 10032 800496512 501(c)(3) 91000 N/A funding to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients. ALECTOR LLC 151 OYSTER POINT BLVD S SAN FRANCISCO CA 94080 140870 N/A funding to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients. NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167817 501(c)(3) 558379 N/A funding to accelerate research and clinical trials in an effort to rapidly bring new therapeutic options to patients. 4 1 X 2 50178 stock price false false false Form 990, part vi, section b, line 11a Board review of form 990 The Foundation's form 990 is prepared by an independent accounting firm based on information provided by the Foundation. The draft prepared by the accounting firm is then provided to the Foundation's board of directors for review and comment prior to filing with the Internal Revenue Service.